Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.
Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.
Open Orphan plc has changed its name to hVIVO plc (Ticker: HVO)
Watch hVIVO’s Capital Markets Day 2022 presentation here.
We are a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and longstanding client base of biopharma companies
Yamin 'Mo' Khan
CEO at hVIVO
"The record numbers we have been able to announce in our trading update for 2022 is the result of the hard work by everyone at hVIVO over the last 12 months. The goal for hVIVO has always been to establish a long-term sustainable growth model. We now have excellent profitable momentum, with full year 2022 EBITDA margin and cash significantly ahead of market expectations, while revenue shows substantial year-on-year growth. These results signify our successes of 2022 and also lay the foundations for FY23 and beyond. The record contracted orderbook not only covers over 95% of the FY23 revenue targets but also gives us visibility well into 2024.
"With the increasing prevalence and severity of infectious and respiratory diseases, there is a vital need for new vaccines and antivirals; as the human challenge partner of choice to the global biopharma industry, hVIVO is well placed to continue to help accelerate the development of these important new medicines."
2022 Revenue
2022 EBITDA Margin
Cash 31 Dec 2022
2023 Revenue Target
Strong market dynamics
Scalable infrastructure
Trusted Partner
Orderbook growth
Our values
We work as one high performing team, each playing to our best, committed to delivering shared goals with passion, energy and enthusiasm. Succeeding together is as important as succeeding individually. We celebrate that success together.
We are committed to growing and developing our employees, professionally and personally, through our unique experiences in a scientifically, intellectually, pioneering environment. Our vision is inspiring, opening up unexplored opportunities and the ability to achieve.
We take personal ownership for our actions and always act in ways that build trust and
respect with the people around us. We believe in clear, open and honest
communication.
We are pioneering in our approach, working with level headedness and listening to each other’s ideas. We are courageous in embracing new challenges and in our determination to do things differently and better. Our agility allows us to define and redefine our markets.
